Oncothyreon Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RWReeves who wrote (1394)	3/3/2000 11:01:00 AM
From: Pseudo Biologist	Read Replies (2) of 2344

RW, Compared to the immunotherapeutics pipeline at IMMU, BIOM seems pretty fully priced I must have missed news of the two phase III trials for IMMU products. Celltech group? You bet. If IMMU et al. are worth their market caps, CLL is worth 2-3X the current quote. Now, that's a pipeline. Long CLL, no position on BIOM or IMMU; but if you put a gun to my head to choose between the last two, it would be BIOM, eh? PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next